1921
Volume 103, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Novel coronavirus disease (COVID-19) is a highly contagious disease caused by severe acute respiratory distress syndrome coronavirus-2 that has resulted in the current global pandemic. Currently, there is no available treatment proven to be effective against COVID-19, but multiple medications, including hydroxychloroquine (HCQ), are used off label. We report the case of a 60-year-old woman without any cardiac history who developed right bundle brunch block and critically prolonged corrected electrocardiographic QT interval (QTc 631 ms) after treatment for 3 days with HCQ, which resolved on discontinuation of the medication. This case highlights a significant and potentially life-threatening complication of HCQ use.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0376
2020-05-07
2020-09-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/1/tpmd200376.html?itemId=/content/journals/10.4269/ajtmh.20-0376&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2020. Coronavirus Disease 2019 (COVID-19) Situation Report-51. Geneva, Switzerland: WHO.
    [Google Scholar]
  2. Kupferschmidt K, Cohen J, 2020. Race to find COVID-19 treatments accelerates. Science 367: 14121413.
    [Google Scholar]
  3. Cao B et al., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. Available at: 10.1056/NEJMoa2001282.
    [Google Scholar]
  4. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Available at: 10.1016/j.ijantimicag.2020.105949.
    [Google Scholar]
  5. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y, 2020. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. Available at: 10.1016/j.ijantimicag.2020.105955.
    [Google Scholar]
  6. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM, 2018. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41: 919931.
    [Google Scholar]
  7. Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V, 2017. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm 39: 1625.
    [Google Scholar]
  8. Abena PM et al., 2020. Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg. 2020 Apr 22 [ePub ahead of print]. Available at: 10.4269/ajtmh.20-0290.
    [Google Scholar]
  9. Rathi S, Ish P, Kalantri A, Kalantri S, 2020. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis S1473–3099: 30313.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0376
Loading
/content/journals/10.4269/ajtmh.20-0376
Loading

Data & Media loading...

  • Received : 28 Apr 2020
  • Accepted : 04 May 2020
  • Published online : 07 May 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error